CytoMed Therapeutics Limited GDTC 深 滬
等待開盤 03-26 09:30:00 美东时间
1.06
+0.020
+1.92%
華盛通- 最 高1.06
- 今 開1.01
- 成交量 7046股
- 最 低 1.00
- 昨 收 1.04
- 總市值 1243.77万
- 52周最高 3.68
- 市盈率 靜 --
- 換手率 0.06%
- 52周最低 0.7282
- 委 比 71.83%
- 總股本 1173.37万
- 歷史最高 9.25
- 量 比 0.65
- 振 幅 5.77%
- 歷史最低 0.7282
- 每 手 1
- 風險率 0.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Friday's After-Market Session
Gainers CytoMed Therapeutics (NASDAQ:GDTC) shares moved upwards by 6.9% to $1....
02-14 05:06
Why Align Technology Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Shares of Align Technology Inc (NASDAQ:ALGN) rose sharply in pre-market trading...
02-05 17:34
CytoMed Therapeutics Refutes Recent Statements Regarding Inaccurate, Misleading Claims About Company's Research Programs, Clinical Progress, And Operations
CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable
01-28 23:02
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
CytoMed Therapeutics Limited, a Singapore-based clinical-stage biopharmaceutical company, issued a statement refuting recent inaccurate and misleading claims about its research programs, clinical progress, and operations. The Company emphasizes its focus on CAR γδ T cell therapies and iPSC-derived γδ NKT cell therapies, with its lead CAR γδ T cell program currently undergoing a first-in-human clinical trial at National University Hospital, Singap...
01-28 15:00
CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital
CytoMed Therapeutics Limited announced its plans for 2026, focusing on expanding its product pipeline through clinical-grade cord blood-derived Natural Killer (NK) cells and continuing its gamma delta T cell therapy development. The company has received support from Enterprise Singapore for its NK cell therapy efforts and is collaborating with Universiti Malaya to conduct a Phase I clinical trial for no-option cancer patients in Malaysia. CytoMed...
01-13 13:00
CytoMed Therapeutics Enters Into MOU With UMMC To Establish Phase I Clinical Trial To Investigate Safety And Efficacy Of CytoMed's Patented Allogeneic Unmodified Gamma Delta T Cells For No-Option Cancer Patients In Malaysia
CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable
2025-12-08 21:08
CytoMed Therapeutics' LongevityBank Secures A Non-Dilutive Investment From ICH Capital Of Up To $500K
CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived
2025-11-06 21:30
CytoMed Therapeutics’ chairman increases effective holdings to 21.95%
CytoMed Therapeutics (NASDAQ:GDTC) said on Wednesday that its executive chairman and substantial shareholder, Peter Choo, has increased his shareholding in the company through recent open-market purch...
2025-10-22 20:46
CytoMed Therapeutics Submits Cash Bid To Acquire TC BioPharm; Terms Not Disclosed
SINGAPORE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary
2025-10-14 20:04
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
CytoMed Therapeutics Limited has submitted a cash bid to acquire certain assets of TC BioPharm Limited (TCBL), another clinical-stage biopharmaceutical company focused on donor-derived allogeneic gamma delta T cells for cancer treatment. The proposed acquisition aims to enhance CytoMed’s expertise in cell therapies, accelerate commercialization, and provide affordable treatment options for cancer patients globally. TCBL has completed a Phase I cl...
2025-10-14 12:00
